Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from ENDRA Life Sciences ( (NDRA) ) is now available.
On October 29, 2025, ENDRA Life Sciences Inc. entered into an At-The-Market Issuance Sales Agreement with Lucid Capital Markets, allowing the company to sell shares of its common stock for up to $1,750,000. This agreement provides ENDRA with flexibility in raising capital through equity offerings, potentially impacting its financial strategy and market presence.
The most recent analyst rating on (NDRA) stock is a Buy with a $38.00 price target. To see the full list of analyst forecasts on ENDRA Life Sciences stock, see the NDRA Stock Forecast page.
Spark’s Take on NDRA Stock
According to Spark, TipRanks’ AI Analyst, NDRA is a Underperform.
ENDRA Life Sciences is currently facing significant financial and operational challenges, with no revenue generation and persistent losses. Despite some short-term technical momentum, the lack of profitability and unattractive valuation metrics weigh heavily on the stock’s potential. Immediate improvements in financial performance and strategic direction are crucial for enhancing its outlook.
To see Spark’s full report on NDRA stock, click here.
More about ENDRA Life Sciences
ENDRA Life Sciences Inc. operates in the healthcare industry, focusing on developing and commercializing advanced medical imaging technology and products.
Average Trading Volume: 282,918
Technical Sentiment Signal: Sell
Current Market Cap: $5.84M
See more data about NDRA stock on TipRanks’ Stock Analysis page.